The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Haiyang, Meng, Xiaoyu, Yao, Yu, Xu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714676/
https://www.ncbi.nlm.nih.gov/pubmed/36465634
http://dx.doi.org/10.3389/fendo.2022.1033479
_version_ 1784842279169556480
author Du, Haiyang
Meng, Xiaoyu
Yao, Yu
Xu, Jun
author_facet Du, Haiyang
Meng, Xiaoyu
Yao, Yu
Xu, Jun
author_sort Du, Haiyang
collection PubMed
description Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects. GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing Aβ deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD. However, this needs to be verified by further clinical trials. This study aims to summarize the current information on the mechanisms and effects of GLP-1R agonists in AD.
format Online
Article
Text
id pubmed-9714676
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97146762022-12-02 The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease Du, Haiyang Meng, Xiaoyu Yao, Yu Xu, Jun Front Endocrinol (Lausanne) Endocrinology Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects. GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing Aβ deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD. However, this needs to be verified by further clinical trials. This study aims to summarize the current information on the mechanisms and effects of GLP-1R agonists in AD. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9714676/ /pubmed/36465634 http://dx.doi.org/10.3389/fendo.2022.1033479 Text en Copyright © 2022 Du, Meng, Yao and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Du, Haiyang
Meng, Xiaoyu
Yao, Yu
Xu, Jun
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
title The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
title_full The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
title_fullStr The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
title_full_unstemmed The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
title_short The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
title_sort mechanism and efficacy of glp-1 receptor agonists in the treatment of alzheimer’s disease
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714676/
https://www.ncbi.nlm.nih.gov/pubmed/36465634
http://dx.doi.org/10.3389/fendo.2022.1033479
work_keys_str_mv AT duhaiyang themechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease
AT mengxiaoyu themechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease
AT yaoyu themechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease
AT xujun themechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease
AT duhaiyang mechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease
AT mengxiaoyu mechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease
AT yaoyu mechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease
AT xujun mechanismandefficacyofglp1receptoragonistsinthetreatmentofalzheimersdisease

Ejemplares similares